Background
Esophageal squamous cell carcinoma (ESCC) is typically diagnosed at a late state and therefore has a very high mortality rate. It is the sixth leading cause of cancer mortalities worldwide [
1]. The overall 5-year survival rate for patients treated with surgery alone is less than 20%, with a median survival of 13 to 17 months [
2‐
5]. Currently, traditional tumor markers, such as CEA, CYFRA21-1 and SCCA, are used to diagnose and evaluate ESCC progression. However, these tumor markers exhibit a low sensitivity in detecting ESCC. Kawaguchi H demonstrated that the diagnostic sensitivity of CEA was only 17.0% in ESCC [
6]. Mealy K reported that the individual sensitivities of CEA and SCCA for the diagnosis of ESCC were about 28% and 32%, respectively [
7]. Yamamoto K study demonstrated that the sensitivity of CYFRA 21-1 was only 47.9%, although the specificity was 100% [
8]. Likewisely, our previous study reported that CEA and CYFRA21-1 exhibited sensitivities of 13.4% and 32.1% for the detection of ESCC, respectively [
9]. These results indicate that the sensitivity of the traditional ESCC tumor markers is too low to diagnose esophageal cancer diagnosis. Therefore, there is an urgent need to identify tumor markers to improve the sensitivity of ESCC detection.
YKL-40, a secreted glycoprotein, belongs to a group of mammalian proteins with an amino acid sequence that is similar to the 18-glycosyl hydrolase group of bacterial chitinases [
10]. It is secreted by various human cells, such as synovial, cartilage, endothelial, neutrophil and macrophage cells [
11]. YKL-40 is involved in angiogenesis, growth, proliferation, differentiation, and remodeling processes [
12]. Serum YKL-40 levels are elevated in pathological conditions, including inflammation and cancer [
13,
14]. Recently, YKL-40 was reported to be highly expressed in several types of cancers, including ovarian cancer [
15], breast cancer [
16], lung cancer [
17], hepatocellular carcinoma [
18], and glioblastoma [
19]. In addition, serum YKL-40 has been suggested as a potential biomarker for the diagnosis and monitoring of these cancers [
20‐
24].
The diagnostic value of serum YKL-40 in patients with ESCC remains unknown. The goal of our present study is to investigate the levels of YKL-40 expression in ESCC tumor cells and to evaluate the diagnostic performance of serum YKL-40 in ESCC diagnosis compared with the traditional ESCC tumor markers CEA, CYFRA21-1 and SCCA.
Methods
Cell lines
The immortalized esophageal epithelial cell line NE-3, induced by human papillomavirus type 16 E6/E7, was obtained from Dr. Jin (the University of Hong Kong, P.R. China) and was cultured in Keratinocyte-SFM (Invitrogen, Carlsbad, CA) media [
25,
26]. The ESCC cell lines Eca-109, Kyse30, Kyse140, Kyse180, Kyse510 and Kyse520 (Chinese Academy of Sciences, Shanghai, China) were grown in RPMI 1640 (Invitrogen, USA) supplemented with 10% fetal bovine serum [
26].
Serum and tissue specimen
Serum from 150 ESCC patients (ages 30-96 years, median 58 years) was collected at the time of diagnosis before tumor resection at the Cancer Center of Sun Yat-Sen University from 2002 to 2005. The patient characteristics are described in Table
1. The absence of disease such as COPD and second primary carcinomas was assessed by clinical history, physical examination, routine laboratory tests (including liver and renal function tests), and colonoscopy. Serum from 126 healthy donors without inflammation (ages 22-78 years, median = 54 years, 74 males and 52 females) were collected from the physical examination department at the Cancer Center of Sun Yat-Sen University. Serum of 59 patients (ages 21-80 years, median = 55 years, 35 males and 24 females) with benign esophageal disease (40 cases of reflux esophagitis, 6 cases of acute suppurative esophagitis and 13 cases of esophageal hiatal hernia) were collected at the first affiliated hospital of Sun Yat-sen University. Venous blood (3-5 ml) was obtained at the time of diagnosis before treatment, clotted at room temperature, centrifuged at 3000 r/min for 10 min and stored at -80°C until use.
Table 1
Levels of YKL-40 and clinical characteristics of patients with ESCC
Age, years |
<60 | 81 | 71.56(6.95-340.70) | 0.001 |
≥60 | 69 | 122.36(21.32-502.05) | 0.001 |
Gender |
Male | 113 | 93.12(11.56-430.83) | 0.784 |
Female | 37 | 111.60(6.95-502.05) | 0.784 |
pT status |
pT1 | 5 | 93.12(21.32-264.66) | 0.975 |
pT2 | 21 | 104.27(30.26-430.83) | 0.975 |
pT3 | 65 | 91.55(6.95-421.34) | 0.975 |
pT4 | 45 | 101.50(14.64-351.66) | 0.975 |
pN status |
pN0 | 57 | 97.27(6.95-430.83) | 0.617 |
pN1 | 77 | 97.03(13.32-421.34) | 0.617 |
pM status |
pM0 | 107 | 93.24(6.95-430.83) | 0.198 |
pM1 | 32 | 108.82(14.64-419.22) | 0.198 |
pTNM status |
Stage I | 7 | 93.12(42.26-264.66) | 0.604 |
Stage II | 40 | 97.27(6.95-430.83) | 0.604 |
Stage III | 58 | 92.40(13.32-421.34) | 0.604 |
Stage IV | 32 | 108.82(14.64-419.22) | 0.604 |
Tumor grade |
Grade 1 | 24 | 108.39(24.95-234.89) | 0.579 |
Grade 2 | 57 | 94.21(11.56-376.09) | 0.579 |
Grade 3 | 41 | 71.02(6.95-419.22) | 0.579 |
A total of 20 formalin-fixed and paraffin-embedded ESCC tumor specimens for immunochemistry were obtained at the Sun Yat-sen University Cancer Center from November of 2012 to December of 2013. Six pairs Real-time RT-PCR and Western-blotting tissue samples were obtained from 2011 to 2013. The corresponding normal esophageal tissue specimens (n = 20) were taken from areas a standard distance (8 cm) from the corresponding resected tumors. All these ESCC and carcinoma-adjacent tissue samples were collected immediately after surgical resection and confirmed by pathological review.
Prior to use of these serum and tissues, informed consent was obtained from each of the participants. All patients provided written informed consent. This experiment was approved by the Institute Research Ethics Committee of the Cancer Center of Sun Yat-Sen University, Guangzhou, China.
Real-time RT-PCR
Total RNA was extracted from cell lines and frozen ESCC tissues using the Trizol reagent (Invitrogen, USA) according to the manufacture’s instruction.
Reverse transcription of total RNA (2 μg) was done using SuperScript II reverse transcriptase. The quantification of target and reference (GAPDH) genes was performed in triplicate on a LightCycler® 480 II (Roche, Applied Science) using a SYBR green-based assay (BioRad, USA). The primers used in the real-time RT-PCR reaction were as follows: YKL-40 forward 5′- GAGGATGGAACTTTGGGTCTC-3′ and reverse 5′- TCATTTCCTTGATTAGGGTGGT-3′; and GAPDH, forward 5′-GACTCATGACCACAGTCCATGC-3′ and reverse 5′-AGAGGCAGGGATGATGTTCTG-3′.
Western blotting analysis
Western blot analysis was performed via standard protocols with antibodies to YKL-40 and α-tublin (Abcam, UK).
Immunohistochemistry
Formalin-fixed, paraffin-embedded ESCC sections were incubated with a rabbit polyclonal anti-YKL-40 antibody (1:100, Bioss, China) overnight at 4°C. After washing in PBST, the tissue sections were treated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:1000, Zymed). The tissue sections were then developed with 3-diaminobenzidine tetrahydrochloride for 10 seconds, followed by counterstaining with 10% Mayer’s hematoxylin. The degree of immunostaining was reviewed by two independent observers.
ELISA
Serum YKL-40 levels were determined by double-antibody sandwich ELISA according to the manufacturer’s instructions (R&D systems, USA). Briefly, 96-well microplates were coated with 100 μl/well of the capture antibody (rat anti-human YKL-40, 2.0 μg/ml) overnight at 4 C. After blocking with 3% BSA, 100 μl of the test samples (1:100 diluted in 1% BSA) was added and incubated for 2 h at room temperature. Subsequently, 100 μl/well of the detection antibody (biotinylated goat anti-human YKL-40, 200 ng/ml) was added and incubated for 2 h at room temperature. Next, 100 μl/well of Streptavidin-HRP (1:200) was added and incubated for 20 min at room temperature. Finally, the substrate (tetramethylbenzidine) solution was added, and the reaction was stopped with 2 N H2SO4 and read at an OD of 450 nm. Each test included a standard control (CV = 12%).
CEA, CYFRA21-1 and SCCA assay
The concentrations of CEA and CYFRA21-1 in the serum were assessed using electrochemiluminescence immunoassay (ECLIA) kits (CEA, lot: 172356; CYFRA21-1, lot: 169393; Roche, German) on a Roche E170 fully automatic electrochemistry luminescence immunity analyzer (Roche, German). The levels of SCCA in the serum were detected using an ARCHITECT I2000SR immune analyze system (Abbott, America) (SCCA, lot: 34111LP68; Abbott, America). Each test included a standard control (CV < 5%).
Statistical analysis
Statistical analyses were performed with the SPSS 16.0 (SPSS Inc.) The relationships between the expression of YKL-40 protein and the clinicopathologic features were analyzed by the Mann-Whitney U test. The comparisons of YKL-40 concentration among different groups were assessed using the Kruskal-Wallis test. The efficacy of YKL-40 was evaluated by the area under receiver operating characteristic (ROC) curve (AUC). The cut-off value for YKL-40 was defined as the value with the maximization of the Yuden index. Furthermore, sensitivity (Sen), specificity (Spe), positive predictive value (PPV) and negative predictive value (NPV) were used to compare the efficiency of diagnosis among YKL-40, CEA, CYFRA21-1 and SCCA. All statistical tests were two-sided, and p < 0.05 was considered statistically significant.
Discussion
In the present study, we found that YKL-40 protein is expressed in ESCC cell lines and ESCC tumor tissues. Serum YKL-40 levels were significantly elevated in patients with ESCC compared with patients with benign diseases and healthy controls. Serum YKL-40 in combination with SCCA significantly increased the sensitivity of detecting ESCC compared with the traditional ESCC tumor markers CEA, CYFRA21-1 and SCCA.
A number of studies have reported that YKL-40 is expressed in tumor cells [
27‐
30]. Due to post-transcriptional regulation, there are some inconsistencies between mRNA and protein expression among the esophageal cancer cell lines. However, in general, YKL-40 was up-regulated in esophageal cancer cell lines and tumor tissue both at the transcriptional and translational level compared to the immortalized esophageal epithelial cell line NE-3 and paired adjacent noncancerous tissue, respectively. Subsequently, using immunohistochemistry analysis, YKL-40 expression was observed in 17 (85.0%) of 20 ESCC tumor tissues but not in neighboring normal esophageal epithelium. These data suggested that YKL-40, expressed in ESCC tumor cells and secreted into the media of tumor cell culture, may be a candidate tumor marker for the detection of ESCC.
Because YKL-40 is a secreted protein expressed in tumor cells, it has been investigated as a tumor marker in many types of cancers. In this study, we tested whether serum YKL-40 could be used as a tumor marker for ESCC. Serum YKL-40 levels in the ESCC group were much higher than in healthy controls. Considering that elevated serum YKL-40 levels were observed in patients with inflammation and the possible influence of chronic inflammation, we examined YKL-40 expression in a set of patients with benign esophageal disease and accompanying chronic inflammation (N = 59) to study whether inflammation would affect the serum levels of YKL-40. Our results demonstrated that the serum YKL-40 levels of patients with benign diseases were significantly higher than those of healthy controls (
p < 0.0001) but significantly lower than those of the ESCC group (
p = 0.038). These data indicate that patients with benign disease and elevated serum YKL-40 levels exhibit inflammation and that ESCC patients express higher levels of serum YKL-40 than do patients with benign diseases. A number of studies have demonstrated that the development of ESCC is associated with chronic inflammation [
31‐
34]. Our previous study and others determined that the inflammation markers SAA and CRP are significantly elevated in patients with ESCC [
9]. Both ESCC tumor cells secreting YKL-40 and inflammation factors increasing YKL-40 expression may account for the higher serum levels of YKL-40 observed in ESCC patients. Our data show that YKL-40 is not able to distinguish between patients with benign disease and early-stage ESCC (p = 0.2126), possibly due to our small sample size of early-stage ESCC patients, which was caused by the difficultly in achieving early diagnosis. In addition, we observed no correlation between the preoperative serum level of YKL-40 and patient disease characteristics, with the exception of age (
p = 0.001). There was no significant difference in serum YKL-40 levels between patients with early-stage tumors (I-II) and patients with advanced-stage tumors (III-IV). These results indicate that serum YKL-40 can be used for the detection early ESCC as well as for the detection advanced ESCC.
CEA, CYFRA21-1 and SCCA are the most commonly investigated tumor markers for the diagnosis of ESCC [
7]. In this study, ROC curve analysis revealed that the accuracy of serum YKL-40 for the diagnosis of ESCC was superior that of CEA, CYFRA21-1, and SCCA. In line with previous studies [
6‐
9], CEA, CYFRA 21-1 and SCCA exhibited low sensitivity but high specificity for ESCC detection in our study. However, compared with CEA, CYFRA 21-1 and SCCA, serum YKL-40 exhibited higher sensitivity and slightly lower specificity. The effect of inflammation factors on the serum levels of YKL-40 may have led to the lower specificity of serum YKL-40 in the diagnosis of ESCC.
CEA, CYFRA 21-1 and SCCA alone exhibit low sensitivity for the diagnosis of ESCC. Researchers have demonstrated that combinations of tumor markers can marginally improve diagnostic efficacy compared with single markers [
7,
35,
36]. In the present study, the addition of YKL-40 to CEA (74.00%), CYFRA21-1(82.00%) or SCCA (82.00%) increased the diagnostic sensitivity compared with CEA (8.00%), CYFRA21-1 (40.00%) or SCCA (32.67%) alone, but the diagnostic specificity did not significantly decrease. Consistent with the report of Munck-Wikland et al. [
37], our results demonstrated that reliance on the three traditional tumor markers CEA, CYFRA21-1 and SCCA for the detection of ESCC is not satisfactory, especially in light of the poor sensitivity (46.81%). However, the combination of YKL-40 and SCCA significantly improved the sensitivity of the detection of ESCC and was superior to the sensitivity of the three traditional tumor markers CEA, CYFRA21-1 and SCCA. Moreover, the YKL-40 and SCCA combination increased the NPV, which can more accurately differentiate patients from healthy individuals. ROC analysis also confirmed that YKL-40 in combination with SCCA was the best model for discriminating between ESCC cases and controls. Moreover, YKL-40 combined with SCCA also served as a more sensitive tumor maker for the detection of patients with early-stage ESCC. Although an analysis of additional patients is needed to verify and expand the present results, our data indicate that the addition of YKL-40 to the traditional ESCC tumor marker SCCA may significantly improve the sensitivity of the detection of ESCC.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests. There are no non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.
Authors’ contributions
In these studies, XZ and SX carried out the main work and contributed equally. They participated in the design of the study and performed the statistical analysis and drafted the manuscript. XML carried out the immunoassays. WLL and other authors conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.